Consensus on molecular imaging and theranostics in prostate cancer
Por:
Fanti, S, Minozzi, S, Antoch, G, Banks, I, Briganti, A, Carrio, I, Chiti, A, Clarke, N, Eiber, M, De Bono, J, Fizazi, K, Gillessen, S, Gledhill, S, Haberkorn, U, Herrmann, K, Hicks, RJ, Lecouvet, F, Montironi, R, Ost, P, O'Sullivan, JM, Padhani, AR, Schalken, JA, Scher, HI, Tombal, B, van Moorselaar, RJA, Van Poppel, H, Vargas, HA, Walz, J, Weber, WA, Wester, HJ, Oyen, WJG
Publicada:
1 dic 2018
Resumen:
Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.
Filiaciones:
Fanti, S:
Univ Bologna, Policlin S Orsola, Nucl Med Div, I-40138 Bologna, Italy
Minozzi, S:
Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy
Antoch, G:
Univ Dusseldorf, Med Fac, Dept Diagnost & Intervent Radiol, Dusseldorf, Germany
Banks, I:
European Canc Org, Ulster, North Ireland
European Mens Hlth Forum, Ulster, North Ireland
Briganti, A:
Ist Ricovero & Cura Carattere Sci Osped San Raffa, Div Oncol, Milan, Italy
Ist Ricovero & Cura Carattere Sci Osped San Raffa, Unit Urol, Urol Res Inst, Milan, Italy
Carrio, I:
Hosp Santa Creu & Sant Pau, Dept Nucl Med, Barcelona, Spain
Chiti, A:
Humanitas Univ, Milan, Italy
Humanitas Res Hosp, Milan, Italy
Clarke, N:
Christie Hosp, Manchester, Lancs, England
Eiber, M:
Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, Munich, Germany
De Bono, J:
Inst Canc Res, London, England
Fizazi, K:
Inst Gustave Roussy, Dept Canc Med, Paris, France
Gillessen, S:
Christie Hosp, Manchester, Lancs, England
Univ Manchester, Div Canc Sci, Manchester, Lancs, England
Kantonsspital St Gallen, Div Oncol, Bern, Switzerland
Kantonsspital St Gallen, Div Haematol, Bern, Switzerland
Univ Bern, Bern, Switzerland
Gledhill, S:
Movember Fdn, Melbourne, Vic, Australia
Haberkorn, U:
Univ Hosp Heidelberg, Dept Nucl Med, Heidelberg, Germany
Univ Hosp Heidelberg, German Canc Res Ctr Heidelberg, Heidelberg, Germany
Herrmann, K:
Univ Klinikum Essen, Dept Nucl Med, Essen, Germany
Hicks, RJ:
Peter MacCallum Canc Inst, Canc Imaging, Melbourne, Vic, Australia
Lecouvet, F:
Catholic Univ Louvain, Clin Univ St Luc, Inst Rech Expt & Clin, Brussels, Belgium
Montironi, R:
Polytech Univ Marche Reg, Inst Pathol Anat & Histopathol, Genitourinary Canc Program, Ancona, Italy
Ost, P:
Ghent Univ Hosp, Genitourinary Program, Ghent, Belgium
O'Sullivan, JM:
Queens Univ, Dept Radiotherapy & Expt Canc Res, Belfast, Antrim, North Ireland
Padhani, AR:
Mt Vernon Hosp, Mt Vernon Canc Ctr, London, England
Schalken, JA:
Radboud Univ Nijmegen, Med Ctr, Dept Expt Urol, Nijmegen, Netherlands
Scher, HI:
Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA
Tombal, B:
Catholic Univ Louvain, Clin Univ St Luc, Inst Rech Expt & Clin, Brussels, Belgium
van Moorselaar, RJA:
Vrije Univ Univ, Med Ctr, Dept Urol, Amsterdam, Netherlands
Van Poppel, H:
Katholieke Univ Leuven, Univ Hosp, Urol, Leuven, Belgium
Vargas, HA:
Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA
Walz, J:
Inst Paoli Calmettes, Canc Ctr, Dept Urol, Marseille, France
Weber, WA:
Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, Munich, Germany
Wester, HJ:
Tech Univ Munich, Lehrstuhl Pharmazeut Radiochem, Garching, Germany
Oyen, WJG:
Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands
Inst Canc Res, Dept Nucl Med, London, England
Royal Marsden Natl Hlth Serv Fdn Trust, London, England
|